search

Active clinical trials for "Nasopharyngeal Carcinoma"

Results 291-300 of 651

Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer...

Nasopharyngeal Neoplasms

This is a study of pembrolizumab (MK-3475) versus standard treatment (capecitabine, gemcitabine, or docetaxel) for the treatment of recurrent or metastatic nasopharyngeal cancer (NPC). Participants will be randomly assigned to receive either pembrolizumab or Investigator's choice of standard treatment. The primary study hypothesis is that pembrolizumab treatment prolongs Overall Survival (OS) when compared to standard treatment. With Amendment 7 (effective 2-March-2022), upon study completion, participants will be discontinued and may be enrolled in an extension study.

Completed26 enrollment criteria

A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)

Cancer

To characterize the safety profile of ARGX-110 administered as mono- or combination therapy to patients with NPC at various stages of its natural history (adjuvant vs. metastatic).

Completed18 enrollment criteria

HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA) for Nasopharyngeal...

Nasopharyngeal Carcinoma

The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction angiography(DSA) for nasopharyngeal carcinoma.

Completed10 enrollment criteria

Different Chemotherapy Protocols Combined With Intensity Modulated Radiation Therapy in Patients...

Drug-Related Side Effects and Adverse Reactions

This study was to evaluate the efficacy ,toxic reaction and safety of different chemotherapy combined with radiotherapy on patients with locally advanced nasopharyngeal carcinoma.

Completed2 enrollment criteria

A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC...

Nasopharyngeal Carcinoma

This is an open-label, single center, non-randomized, phase I trial to evaluate safety and efficacy of using the combination treatment of SHR-1210, gemcitabine and cis-platinum by recurrent and metastatic NPC.

Completed29 enrollment criteria

Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma...

Nasopharyngeal Carcinoma

The study is to evaluate the clinical efficacy of apatinib mesylate tablets combined with PD-1 in the treatment of recurrent and metastatic nasopharyngeal carcinoma after IMRT with concurrent chemotherapy,including The Overall Response Rate (ORR), Progression-free survival (PFS),Overall survival (OS),and Toxicities.

Completed24 enrollment criteria

Delineation of Reducing Clinical Target Volume for Early-stage Nasopharyngeal Carcinoma Patients...

Target Volume DelineationEarly-stage Nasopharyngeal Carcinoma1 more

To analyze the long-term results and toxicities of the reducing clinical target volume (CTV) delineation method in early-stage nasopharyngeal carcinoma (NPC) patients treated with intensity modulated radiation therapy (IMRT).

Completed11 enrollment criteria

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

MelanomaBreast Carcinoma26 more

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.

Completed52 enrollment criteria

Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer...

CarcinomaSquamous Cell of Head and Neck5 more

This research study is evaluating a drug called buparlisib (BKM120) as a possible treatment for locally advanced head and neck squamous cell cancer.

Completed40 enrollment criteria

Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)

Nasopharyngeal Carcinoma

The investigators will add weekly cetuximab (c225) to the standard care of chemoradiation against locoregionally advanced Nasopharyngeal Carcinoma (NPC), and evaluate the toxicity and efficacy of this new regimen.

Completed11 enrollment criteria
1...293031...66

Need Help? Contact our team!


We'll reach out to this number within 24 hrs